Dry Eye Rescue Is Offering Friends Of MDA A 20% Discount On All Products To Help With Your Eye Conditions

Click Here To Save Now

Resources

Dec 1, 2025

Judi Dench Says She ‘Can’t Recognize Anybody’ Due to Eye Condition: ‘I Can’t See Anymore’

by: Jack Dunn Judi Dench recently shared that she “can’t recognize anybody” due to her eye condition. When asked by ITV why she’s stepped away from acting, Dench told the outlet, “I can’t…

Judi Dench Says She ‘Can’t Recognize Anybody’ Due to Eye Condition: ‘I Can’t See Anymore’

Dec 1, 2025

#GivingTuesday 2025

Join us for #GivingTuesday2025 on Tuesday, December 2nd, from 12:00 AM to 11:59 PM! Your generous support can make a transformative impact in our fight against macular degeneration. Together, we…

#GivingTuesday 2025

Nov 26, 2025

Happy Thanksgiving

Happy Thanksgiving! The Macular Degeneration Association would like to express our gratitude for your support and thoughtfulness. “As we show our appreciation, we must remember that the highest form of…

Happy Thanksgiving

Nov 26, 2025

Low Vision vs Legally Blind: What’s the difference?

Dr. Long, thank you for explaining the difference between low vision and legal blindness. Low vision vs. legally blind—what’s the difference? The terms “low vision” and “legally blind” are often…

Low Vision vs Legally Blind: What’s the difference?

Nov 25, 2025

New Stem Cell Therapy Trial Offers Hope for Millions Living with Untreatable Advanced Dry Macular Degeneration

The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety issues are identified, the investigators plan to move on…

New Stem Cell Therapy Trial Offers Hope for Millions Living with Untreatable Advanced Dry Macular Degeneration

Nov 25, 2025

FDA approves Eylea HD for macular edema after retinal vein occlusion

By: Anthony DeFino Fact checked by: Nancy Hemphill, ELS, FAAO Key takeaways: The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is…

FDA approves Eylea HD for macular edema after retinal vein occlusion

Nov 24, 2025

GLP-1s may double risk for development of wet AMD

By Justin Cooper Fact checked by; Christine Klimanskis, ELS Key takeaways: Patients with diabetes taking GLP-1s had a twofold higher risk for wet AMD development in unadjusted and adjusted models.…

GLP-1s may double risk for development of wet AMD

Nov 24, 2025

EYE on MACULAR CAROTENOIDS: Diet & Supplementation

You’ve heard of Vitamin A for your eyes… but did you know there’s a family of natural pigments that may be even more essential for protecting your vision? 👁️ In…

EYE on MACULAR CAROTENOIDS: Diet & Supplementation

Nov 21, 2025

8 Foods That Fight Inflammation Even Better Than Ginger

By Anna Giorgi  Published on November 18, 2025  Medically reviewed by Karina Tolentino, RD Ginger is one of several foods that may have strong anti-inflammatory effects. Ginger isn’t the only anti-inflammatory food,…

8 Foods That Fight Inflammation Even Better Than Ginger

Nov 18, 2025

Enjoying the Winter Wonderland: A Winter Eyecare Guide

  As winter sets in, many of us may experience symptoms that differ from those in other times of the year. One common issue that tends to worsen in winter…

Enjoying the Winter Wonderland: A Winter Eyecare Guide

Nov 18, 2025

Apellis announces 5-year GALE study data in GA

Author(s): Kassi Filkins Fact checked by: Kirsty Mackay Key Takeaways SYFOVRE (pegcetacoplan injection) delays GA lesion growth by approximately 1.5 years compared to sham treatment in AMD patients. The GALE study,…

Apellis announces 5-year GALE study data in GA

Nov 17, 2025

The Eye Q Podcast Episode 49

In this episode of The Eye-Q Podcast, Dr. Rani Banik sits down with Dr. Debbie Ozment—an integrative dentist with over 40 years of experience—to explore the mouth-body connection. They discuss…

The Eye Q Podcast Episode 49

Nov 11, 2025

Happy Veterans Day

Happy Veterans Day. Thank you to all who serve and their families for their sacrifices. “As we express our gratitude, we must never forget that the highest appreciation is not…

Happy Veterans Day

Nov 7, 2025

eSight Go headset ‘gives you your central perception back’

By: Justin Cooper Fact checked by: Christine Klimanskis, ELS Key takeaways: eSight Go uses two OLED screens to boost visual acuity for people with central vision loss. The device is…

eSight Go headset ‘gives you your central perception back’

Nov 6, 2025

GLP-1s may double risk for development of wet AMD

By: Justin Cooper Fact checked by: Christine Klimanskis, ELS Key takeaways: Patients with diabetes taking GLP-1s had a twofold higher risk for wet AMD development in unadjusted and adjusted models.…

GLP-1s may double risk for development of wet AMD

Nov 5, 2025

Smart eye wear ‘definitely having a moment’ with jump in consumer awareness

By: Justin Cooper Fact checked by: Christine Klimanskis, ELS Key takeaways: Consumers are more familiar with smart eye wear than they were 2 years ago. Social media is the main…

Smart eye wear ‘definitely having a moment’ with jump in consumer awareness

Nov 4, 2025

Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial

Author(s) : Martin David Harp Key Takeaways AXPAXLI is a bioresorbable hydrogel incorporating axitinib, targeting wet AMD and other retinal diseases with anti-angiogenic properties. The SOL-R trial compares AXPAXLI’s six-month dosing…

Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial

Oct 30, 2025

Research supports that iron dysregulation may drive AMD

Author(s): Sydney M Crago Key Takeaways Iron dysregulation contributes to oxidative stress, inflammation, and ferroptosis, driving retinal degeneration in dry AMD and GA. Transferrin, regulating iron homeostasis, is a potential…

Research supports that iron dysregulation may drive AMD

Oct 24, 2025

Starting from scratch on neovascular age-related macular degeneration

Author(s): Lynda Charters Key Takeaways Gene therapy for nAMD offers potential to reduce treatment burden and improve vision, but long-term safety and efficacy remain concerns. Various gene delivery systems, including…

Starting from scratch on neovascular age-related macular degeneration

Oct 16, 2025

Consumer technology has limitations for assistive needs

By: Roland Mattern Fact checked by: Christine Klimanskis, ELS Key takeaways: Accessibility features in mainstream technology are not as reliable as those in dedicated assistive devices. Purpose-built assistive technology has…

Consumer technology has limitations for assistive needs

Oct 10, 2025

Sharper vision starts here

Sharper vision starts here Author(s)Jack M. Chapman, MD Fact checked by: Sheryl Stevenson Key Takeaways Over 75% of cataract patients have preoperative corneal astigmatism, yet toric IOLs are used in only…

Sharper vision starts here

Oct 10, 2025

Seeing Stars: Gould & Steele interview

Permission was given by Martha Steele & Ellen Gould to share this podcast.

Seeing Stars: Gould & Steele interview

Oct 8, 2025

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight

Publication|Articles|October 6, 2025 Optometry Times Journal September/October digital edition 2025- Volume 17 –  Issue 05 Author(s)Lynda Charters Fact checked by: Karen S. DeLoss, OD, FAAO Eye care providers are uniquely positioned to…

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight

Sep 26, 2025

Seeing Through the Fog: Understanding Macular Degeneration

Helping with reading, driving, and daily tasks, caregivers often serve as the ‘eyes’ for their loved ones By: Paul Wynn,AARP In her early 40s, Jan* began noticing subtle but troubling…

Seeing Through the Fog: Understanding Macular Degeneration

Sep 23, 2025

New eyedrop raises hopes for less invasive treatment of serious vision conditions

A new eyedrop has shown early success in delivering protective compounds to where they’re needed most in the eye, raising hopes for less invasive treatment of serious vision conditions. The…

New eyedrop raises hopes for less invasive treatment of serious vision conditions

Sep 23, 2025

Adult Stem Cells Show Therapeutic Promise in Treating Vision Loss From Macular Degeneration

Adult Stem Cells Show Therapeutic Promise in Treating Vision Loss From Macular Degeneration by: Michigan Medicine-University of Michigan Newswise — In the United States, age-related macular degeneration is a leading…

Adult Stem Cells Show Therapeutic Promise in Treating Vision Loss From Macular Degeneration

Sep 16, 2025

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Recruiting- Phase 2 ClinicalTrials.gov IDNCT06635148 SponsorJanssen Research & Development, LLC Information Provided byJanssen Research & Development, LLC Clinical Trial Study Start (Actual)2024-09-19 Primary Completion (Estimated) 2029-08-24 Study Completion (Estimated)2030-06-27 Enrollment (Estimated)311…

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Sep 16, 2025

FDA fast tracks SAR402663 intravitreal gene therapy for wet AMD

By:Anthony DeFino Fact checked by: Christine Klimanskis, ELS Key takeaways: SAR402663 is a one-time intravitreal gene therapy designed to reduce treatment burden. It is currently being investigated in a phase…

FDA fast tracks SAR402663 intravitreal gene therapy for wet AMD

Sep 12, 2025

Sight Science’s TearCare System earns spot in TFOS DEWS III dry eye report

Author(s): Martin David Harp Key Takeaways TearCare System’s inclusion in TFOS DEWS III report validates its clinical efficacy and role in dry eye management. Data from studies such as SAHARA…

Sight Science’s TearCare System earns spot in TFOS DEWS III dry eye report

Sep 9, 2025

A study of the progression of sensitivity loss in GA over time using inferred data

Author(s): Lynda Charters Key Takeaways Inferred sensitivity mapping predicts retinal function in GA with high spatial resolution, avoiding extensive psychophysical testing. Current GA treatments slow progression but lack functional benefits;…

A study of the progression of sensitivity loss in GA over time using inferred data

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.